Cambia approved for treatment of migraine

The FDA has approved Cambia (diclofenac potassium oral solution, from Kowa Pharmaceuticals) for the treatment of acute migraine with or without aura in adults ≥18 years old. In randomized clinical trials, Cambia was shown to be effective in relieving migraine pain, with a statistically significant onset of relief within 15 to 30 minutes. Additionally, Cambia was also demonstrated to be effective in treating photophobia, phonophobia, and nausea commonly associated with migraine attacks.

Cambia is expected to be available in early 2010.

For more information call (334) 288-1288 or visit www.kowapharma.com.